Business UpdateMay 11, 2026, 09:22 AM
Biodesix to Present Nodify Lung Data at ATS Annual Meeting
AI Summary
Biodesix, Inc. announced that new real-world clinical and economic data for its Nodify Lung® testing will be presented at the American Thoracic Society (ATS) Annual Meeting from May 15-20, 2026. These presentations will highlight the clinical value and economic advantages of lung nodule management programs utilizing Nodify Lung® testing for risk stratification. The company's CEO, Scott Hutton, emphasized that the data reinforces the accelerating adoption of Biodesix's blood-based tests for earlier lung cancer detection and improved patient outcomes.
Key Highlights
- Biodesix to present additional real-world clinical and economic data for Nodify Lung® testing at ATS Annual Meeting.
- Oral presentation on May 17 by Michael Kammer, PhD, on autoantibody test impact on lung nodule risk.
- Poster presentation on May 18 by Roshen Mathew, MD, on real-world community experience with Nodify Classifiers.
- Poster presentation on May 18 by Maurice Smith, MD, on CLIP impact on lung cancer stage at diagnosis.
- Poster presentation on May 19 by Gerard Silvestri, MD, on PET vs. biomarkers for indeterminate pulmonary nodules.
- Poster presentation on May 19 by Maurice Smith, MD, on stage shift after CLIP implementation.
Price Impact
More from BDSX